MX2022005795A - Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas. - Google Patents

Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas.

Info

Publication number
MX2022005795A
MX2022005795A MX2022005795A MX2022005795A MX2022005795A MX 2022005795 A MX2022005795 A MX 2022005795A MX 2022005795 A MX2022005795 A MX 2022005795A MX 2022005795 A MX2022005795 A MX 2022005795A MX 2022005795 A MX2022005795 A MX 2022005795A
Authority
MX
Mexico
Prior art keywords
chemocine
crystalline forms
type
receptor antagonist
same
Prior art date
Application number
MX2022005795A
Other languages
English (en)
Spanish (es)
Inventor
David J Wustrow
Mikhail Zibinsky
Sami Karaborni
David J Arnold
Omar Robles
Duane E Rudisill
Original Assignee
Rapt Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapt Therapeutics Inc filed Critical Rapt Therapeutics Inc
Publication of MX2022005795A publication Critical patent/MX2022005795A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2022005795A 2019-11-13 2020-11-13 Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas. MX2022005795A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962935007P 2019-11-13 2019-11-13
PCT/US2020/060575 WO2021097339A1 (en) 2019-11-13 2020-11-13 Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof

Publications (1)

Publication Number Publication Date
MX2022005795A true MX2022005795A (es) 2022-06-08

Family

ID=73856569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005795A MX2022005795A (es) 2019-11-13 2020-11-13 Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas.

Country Status (11)

Country Link
US (2) US12006318B2 (https=)
EP (1) EP4058456A1 (https=)
JP (2) JP2023501584A (https=)
KR (1) KR20220101099A (https=)
CN (1) CN114728972B (https=)
BR (1) BR112022009331A2 (https=)
CA (1) CA3158521A1 (https=)
IL (1) IL292755A (https=)
MX (1) MX2022005795A (https=)
WO (1) WO2021097339A1 (https=)
ZA (1) ZA202204943B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058456A1 (en) 2019-11-13 2022-09-21 RAPT Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
CN121002023A (zh) * 2023-04-24 2025-11-21 浙江华海药业股份有限公司 趋化因子受体调节剂制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JP2008530211A (ja) * 2005-02-16 2008-08-07 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体のモジュレーターとなる置換ピラゾール
TW201024298A (en) * 2008-09-23 2010-07-01 Palau Pharma Sa (R)-3-(N,N-dimethylamino)pyrrolidine derivatives
US8383812B2 (en) * 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
JP2013031931A (ja) * 2011-08-01 2013-02-14 Hitachi Koki Co Ltd 携帯式作業機
TW201311693A (zh) * 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
AU2017302635B2 (en) * 2016-07-29 2021-09-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
US10246462B2 (en) * 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JP2020533332A (ja) * 2017-09-12 2020-11-19 アルデア バイオサイエンシーズ インク． 障害を処置するためのｃｘｃｒ−２阻害剤
EP3706750A1 (en) 2017-11-06 2020-09-16 RAPT Therapeutics, Inc. Chemokine receptor modulators for treatment of epstein barr virus positive cancer
CN109796457B (zh) * 2019-03-28 2020-03-06 苏州国匡医药科技有限公司 一种2-(3-(氮杂环丁烷-3-基)哌啶-1-基)乙基-1-醇的制备方法及其应用
EP4058456A1 (en) 2019-11-13 2022-09-21 RAPT Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof

Also Published As

Publication number Publication date
CN114728972A (zh) 2022-07-08
JP2023501584A (ja) 2023-01-18
JP2026012675A (ja) 2026-01-27
US12006318B2 (en) 2024-06-11
AU2020383625A1 (en) 2022-05-05
ZA202204943B (en) 2023-11-29
KR20220101099A (ko) 2022-07-19
WO2021097339A1 (en) 2021-05-20
TW202132303A (zh) 2021-09-01
EP4058456A1 (en) 2022-09-21
IL292755A (en) 2022-07-01
CA3158521A1 (en) 2021-05-20
US20210139487A1 (en) 2021-05-13
US20240317768A1 (en) 2024-09-26
BR112022009331A2 (pt) 2022-08-09
CN114728972B (zh) 2024-12-10

Similar Documents

Publication Publication Date Title
CO2021000043A2 (es) Degradadores selectivos del receptor de estrógeno
CO2019002596A2 (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino
CL2021001790A1 (es) Enlazadores sin trazas, conjugados de proteínas de los mismos y composiciones de los mismos
CO2021000041A2 (es) Degradadores selectivos del receptor de estrógeno
MX390698B (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
MX378566B (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
MX385424B (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
MX385336B (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
MX2024003236A (es) Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
MX383292B (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
MX372781B (es) Ciclopentanos 1,2-sustituidos como antagonistas del receptor de la orexina.
MX2020009286A (es) Antagonistas del receptor de adenosina y usos de los mismos.
MX2017015370A (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
MX2022005795A (es) Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas.
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
CO2019001116A2 (es) Regímenes de dosificación de antagonistas de lingo-1 y usos para el tratamiento de trastornos desmielinizantes
ECSP21010874A (es) Piridopirimidinas como inhibidores del receptor de histamina h4
MX384146B (es) Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.